Abstract 5926
Background
Aberrant methylation is pervasive in cancer and a promising source of diagnostic and predictive biomarkers. Bisulfite conversion, the current standard for detecting methylated cytosines, requires higher DNA input requirements due to destruction of DNA, and is problematic for the low cell-free DNA (cfDNA) recovery from plasma. Enzymatic methyl-seq (EM-Seq) uses enzymatic conversion in place of bisulfite. Here, we compare quality metrics and cancer-associated signals of whole-genome sequenced libraries with bisulfite conversion (WGBS) and EM-Seq.
Methods
We collected blood and isolated cfDNA from 7 healthy controls and 15 participants with cancer. Paired libraries from each participant were prepared using WGBS and EM-seq, were sequenced to a median depth of 1.7x, and processed using a custom bioinformatics pipeline.
Results
The quality of data produced by both methods was largely comparable, including highly correlated methylation levels across CpG islands (average Pearson R = 0.97). However, EM-seq performed better on a number of technical metrics including: higher conversion efficiency, increased alignment quality, and coverage. For library pairs where CNAs were detectable (n = 7), the assessed tumor fractions were similar between the two methods, with 6 out of 7 having estimates within 1.15 fold. WGBS libraries showed evidence of DNA damage, including consistently shorter fragments (7.9 ± 2.1 bp shorter mean length in WGBS relative to paired EM-Seq) and the requirement of more amplification cycles (12 vs 8). Like standard whole genome sequencing, control EM-seq libraries had less variability in genome-wide coverage distributions and preserved the canonical cfDNA fragment length distribution.
Conclusions
Our results show that both approaches produce concordant estimates of methylation levels throughout the genome. However, EM-seq demonstrates a number of advantages, including higher performance in key quality metrics. We conclude that EM-Seq is a suitable method for assessing plasma cell-free methylome in a cancer setting and avoiding bisulfite-associated DNA degradation.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Lexent Bio Inc.
Funding
Lexent Bio.
Disclosure
N. Lambert: Full/Part-time employment: Lexent Bio Inc. A. Robertson: Full/Part-time employment: Lexent Bio Inc. R. Srivas: Full/Part-time employment: Lexent Bio Inc. N. Peterman: Full/Part-time employment: Lexent Bio Inc. J. Close: Full/Part-time employment: Lexent Bio Inc. T. Wilson: Full/Part-time employment: Lexent Bio Inc. P. George: Full/Part-time employment: Lexent Bio Inc. H. Wood: Full/Part-time employment: Lexent Bio Inc. B. Wong: Full/Part-time employment: Lexent Bio Inc. A. Tezcan: Full/Part-time employment: Lexent Bio Inc. H. Tezcan: Full/Part-time employment: Lexent Bio Inc.
Resources from the same session
4321 - Health-related quality of life of advanced melanoma survivors treated with CTLA-4 immune checkpoint inhibition: a matched cohort study
Presenter: Annelies Boekhout
Session: Poster Display session 1
Resources:
Abstract
779 - Capecitabine vs Cisplatin along with concurrent radiotherapy in the treatment of inoperable lower esophageal cancers focusing on TWISTT score and QOL
Presenter: Goutham Anugu
Session: Poster Display session 1
Resources:
Abstract
5914 - Cancer, Mental Health and End Life Simulation (CAMhELS): A novel effectiveness evaluation.
Presenter: Asanga Fernando
Session: Poster Display session 1
Resources:
Abstract
2597 - Cancer patients’ expectations and understanding about their disease
Presenter: Mónica Pinho
Session: Poster Display session 1
Resources:
Abstract
5187 - Impact of patients’ death on oncologists and coping strategies: An online survey
Presenter: Soumaya Labidi
Session: Poster Display session 1
Resources:
Abstract
4579 - Clinical benefit from late lines of therapy offered to patients treated in a tertiary referral centre
Presenter: Andrea Sbrana
Session: Poster Display session 1
Resources:
Abstract
5058 - Preparedness for caregiving in caregivers of cancer patients
Presenter: Hatice Yakar
Session: Poster Display session 1
Resources:
Abstract
5917 - Oncologic Emergency Medicine in the real world: A survey and proposal for improvement
Presenter: Carintia Dorta Pérez
Session: Poster Display session 1
Resources:
Abstract
4077 - The Reality of Critical Cancer Patients in a Polyvalent Intensive Care Unit
Presenter: Tiago Filipe Da Cruz Tomas
Session: Poster Display session 1
Resources:
Abstract
1728 - A phase III trial evaluating olanzapine 5 mg for the prevention of chemotherapy-induced nausea and vomiting in patients receiving cisplatin: J-FORCE Study
Presenter: Hironobu Hashimoto
Session: Poster Display session 1
Resources:
Abstract